Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin Therapy for Healthcare Clinicians With Depression and Loss of Meaning
NCT07565909Phase 2Not yet recruiting
- Sponsor
- University of Washington
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD), anxiety disorder, sponsored by University of Washington. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT07565909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07565909.